More Mesoblast Limited news
Mesoblast LimitedASX: MSB

Key US Patent Granted For Treatment Of Rheumatoid Arthritis

Mar 23, 2016 at 11:45 PM EDT · Issued by Mesoblast Limited

Filed with ASX · Mar 23, 2016 at 11:45 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/key-us-patent-granted-for-treatment-of-rheumatoid-arthritis

Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26↗

Mesoblast Limited on 6ix

Story so far

  • Rheumatoid Arthritis New Major Clinical Target for MSBFeb 11, 2016
  • FDA clears Phase 2 clinical trial for rheumatoid arthritisFeb 11, 2016
  • Key US Patent Granted For Heart, Stroke, Vascular DiseasesFeb 11, 2016

Earlier from Mesoblast

  • GVHD Product Launched In JapanFeb 24, 2016
  • Increased Survival Using MSB Cells In Children With aGVHDFeb 21, 2016
  • Half Yearly Report and Accounts (including Appendix 4D)Feb 16, 2016
  • MSB Therapy Shows Benefit In First Cohort Of RA PatientsFeb 15, 2016
  • Phase 3 Heart Failure Trial Size Substantially ReducedFeb 11, 2016

Later from Mesoblast

  • Circulation Publishes Improved Outcomes with Mesoblast CellsMar 30, 2016
  • Mesoblast Receives $5.05m for Stem Cell Pipeline DevelopmentMar 30, 2016
  • MSB Accelerates Plans for Commercial Manufacturing OperationMar 30, 2016
  • MSB & NIH Agree 120 Patient Trial In End-Stage Heart FailureMar 30, 2016
  • Key European Patent Granted for Mesoblasts MPCsMar 30, 2016
All Mesoblast news releases↗

Follow Mesoblast into a list and get an email when it puts out news.

Follow Mesoblast
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer